Literature DB >> 21167651

Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.

Lamberto Widesott1, Alessio Pierelli, Claudio Fiorino, Antony J Lomax, Maurizio Amichetti, Cesare Cozzarini, Martin Soukup, Ralf Schneider, Eugen Hug, Nadia Di Muzio, Riccardo Calandrino, Marco Schwarz.   

Abstract

PURPOSE: To compare intensity-modulated proton therapy (IMPT) and helical tomotherapy (HT) treatment plans for high-risk prostate cancer (HRPCa) patients. METHODS AND MATERIALS: The plans of 8 patients with HRPCa treated with HT were compared with IMPT plans with two quasilateral fields set up (-100°; 100°) and optimized with the Hyperion treatment planning system. Both techniques were optimized to simultaneously deliver 74.2 Gy/Gy relative biologic effectiveness (RBE) in 28 fractions on planning target volumes (PTVs)3-4 (P + proximal seminal vesicles), 65.5 Gy/Gy(RBE) on PTV2 (distal seminal vesicles and rectum/prostate overlapping), and 51.8 Gy/Gy(RBE) to PTV1 (pelvic lymph nodes). Normal tissue calculation probability (NTCP) calculations were performed for the rectum, and generalized equivalent uniform dose (gEUD) was estimated for the bowel cavity, penile bulb and bladder.
RESULTS: A slightly better PTV coverage and homogeneity of target dose distribution with IMPT was found: the percentage of PTV volume receiving ≥ 95% of the prescribed dose (V(95%)) was on average > 97% in HT and > 99% in IMPT. The conformity indexes were significantly lower for protons than for photons, and there was a statistically significant reduction of the IMPT dosimetric parameters, up to 50 Gy/Gy(RBE) for the rectum and bowel and 60 Gy/Gy(RBE) for the bladder. The NTCP values for the rectum were higher in HT for all the sets of parameters, but the gain was small and in only a few cases statistically significant.
CONCLUSIONS: Comparable PTV coverage was observed. Based on NTCP calculation, IMPT is expected to allow a small reduction in rectal toxicity, and a significant dosimetric gain with IMPT, both in medium-dose and in low-dose range in all OARs, was observed.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167651     DOI: 10.1016/j.ijrobp.2010.10.005

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  18 in total

Review 1.  Evolution of advanced technologies in prostate cancer radiotherapy.

Authors:  Nicholas G Zaorsky; Amy S Harrison; Edouard J Trabulsi; Leonard G Gomella; Timothy N Showalter; Mark D Hurwitz; Adam P Dicker; Robert B Den
Journal:  Nat Rev Urol       Date:  2013-09-10       Impact factor: 14.432

Review 2.  Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

3.  Small bowel toxicity after high dose spot scanning-based proton beam therapy for paraspinal/retroperitoneal neoplasms.

Authors:  R A Schneider; V Vitolo; F Albertini; T Koch; C Ares; A Lomax; G Goitein; E B Hug
Journal:  Strahlenther Onkol       Date:  2013-09-21       Impact factor: 3.621

4.  Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: Robustness analysis through simulation of rotational and translational alignment errors.

Authors:  Thomas J Pugh; Richard A Amos; Sandra John Baptiste; Seungtaek Choi; Quyhn Nhu Nguyen; X Ronald Zhu; Matthew B Palmer; Andrew K Lee
Journal:  Med Dosim       Date:  2013-06-06       Impact factor: 1.482

Review 5.  National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury.

Authors:  Daphne Haas-Kogan; Daniel Indelicato; Harald Paganetti; Natia Esiashvili; Anita Mahajan; Torunn Yock; Stella Flampouri; Shannon MacDonald; Maryam Fouladi; Kry Stephen; John Kalapurakal; Stephanie Terezakis; Hanne Kooy; David Grosshans; Mike Makrigiorgos; Kavita Mishra; Tina Young Poussaint; Kenneth Cohen; Thomas Fitzgerald; Vinai Gondi; Arthur Liu; Jeff Michalski; Dragan Mirkovic; Radhe Mohan; Stephanie Perkins; Kenneth Wong; Bhadrasain Vikram; Jeff Buchsbaum; Larry Kun
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-05-01       Impact factor: 7.038

6.  Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer.

Authors:  Thomas J Pugh; Mark F Munsell; Seungtaek Choi; Quyhn Nhu Nguyen; Benson Mathai; X Ron Zhu; Narayan Sahoo; Michael Gillin; Jennifer L Johnson; Richard A Amos; Lei Dong; Usama Mahmood; Deborah A Kuban; Steven J Frank; Karen E Hoffman; Sean E McGuire; Andrew K Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-10-15       Impact factor: 7.038

Review 7.  Roadmap: proton therapy physics and biology.

Authors:  Harald Paganetti; Chris Beltran; Stefan Both; Lei Dong; Jacob Flanz; Keith Furutani; Clemens Grassberger; David R Grosshans; Antje-Christin Knopf; Johannes A Langendijk; Hakan Nystrom; Katia Parodi; Bas W Raaymakers; Christian Richter; Gabriel O Sawakuchi; Marco Schippers; Simona F Shaitelman; B K Kevin Teo; Jan Unkelbach; Patrick Wohlfahrt; Tony Lomax
Journal:  Phys Med Biol       Date:  2021-02-26       Impact factor: 4.174

Review 8.  Proton therapy for early stage prostate cancer: is there a case?

Authors:  Tabitha Y Chan; Poh Wee Tan; Johann I Tang
Journal:  Onco Targets Ther       Date:  2016-09-09       Impact factor: 4.147

9.  A treatment planning study comparing tomotherapy, volumetric modulated arc therapy, Sliding Window and proton therapy for low-risk prostate carcinoma.

Authors:  Sergiu Scobioala; Christopher Kittel; Nicolas Wissmann; Uwe Haverkamp; Mohammed Channaoui; Omar Habibeh; Khaled Elsayad; Hans Theodor Eich
Journal:  Radiat Oncol       Date:  2016-09-27       Impact factor: 3.481

10.  Dosimetric study of uniform scanning proton therapy planning for prostate cancer patients with a metal hip prosthesis, and comparison with volumetric-modulated arc therapy.

Authors:  Suresh Rana; ChihYao Cheng; Yuanshui Zheng; Wen Hsi; Omar Zeidan; Niek Schreuder; Carlos Vargas; Gary Larson
Journal:  J Appl Clin Med Phys       Date:  2014-05-08       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.